Top Markets
Coin of the day
Arch Biopartners Inc. Arch Biopartners Inc.

Arch Biopartners Inc.

ARCH
Clasificación en acciones #25413
Arch Biopartners Inc. is a biotechnology firm dedicated to devising... Arch Biopartners Inc. is a biotechnology firm dedicated to devising groundbreaking solutions for both medical and commercial applications. A significant focus for the company is the advancement of Metablok, a key therapeutic agent designed to address or avert dipeptidase-1 driven inflammation in critical organs such as the lungs, liver, and kidneys. This inflammatory response can lead to profound organ dysfunction or complete failure, particularly in conditions like sepsis and COVID-19. Moreover, Arch Biopartners is developing AB569, an experimental medication intended to combat antibiotic-resistant bacterial infections, primarily through topical application on wounds. Their innovative product pipeline also features Borg, a specialized peptide-solid surface interface developed to hinder biofilm formation and lessen material corrosion. Lastly, MetaMx involves synthetic compounds engineered to target the cells that initiate brain tumors and invasive glioma cells. The company's operations are based out of Toronto, Canada.
Precio por acción
$0.73393689
Última sincronización: 2026-08-20
Capitalización bursátil
$49.86M
Cambio (1 día)
-8.26%
Cambio (1 año)
-38.15%
País
CA
Comercio Arch Biopartners Inc. (ARCH)

Categoría

Historial de rendimiento por dividendo de Arch Biopartners Inc. (ARCH)
Rendimiento por dividendo (TTM) de Arch Biopartners Inc. (símbolo bursátil: ARCH) al 2026: 0
Rendimiento promedio por dividendo de los últimos 5 años: 0.00%
Historial de rendimiento por dividendo de Arch Biopartners Inc. (ARCH) desde 2026 hasta 2026
Rendimiento por dividendo al final de cada año (TTM)
Año Rendimiento por dividendo Cambiar
Not enough data for the provided dates.
Rendimientos por dividendo (TTM) de empresas similares o competidoras
Empresa Rendimiento por dividendo País
0.00%
US
0.00%
NL
3.12%
AU
0.00%
CH
0.00%
US